Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chemotherapy
Lower-dose topotecan tolerated in patients with pretreated ovarian cancer
November 10th, 2005
Lower-dose topotecan was well tolerated in patients with pretreated ovarian cancer. According to a recent report published in the International Journal of Gynecological Cancer, "Topotecan (1.5 mg/m2/day for 5 consecutive days of a 21-day cycle) is an established recurrent ovarian cancer treatment, but myelosuppression can be dose limiting. This study evaluates the activity and tolerability of low-dose topotecan in our clinical experience." "Case records were reviewed for patients with recurrent ovarian cancer in first through third relapse. Eligible patients had received {{>=}}2 cycles of {{<=}}1.25 mg/m2 topotecan....
Source: Women's Health Weekly (2005-11-10)
|
